Junious Media NetworkSaturday, November 21, 2026
Juni Daily.
Advertisement
Safety & Recalls

FDA Clears Infilbray, First Drug for Type 3 Gaucher Brain Symptoms

The FDA approved Infilbray (venglustat), the first drug to cross the blood-brain barrier and treat neurological symptoms of Type 3 Gaucher disease.

Key points

  1. The FDA approved Infilbray (venglustat) as the first drug to treat neurological symptoms of Type 3 Gaucher disease in adults and children weighing at least 15 kg.
  2. Infilbray works as a glucosylceramide synthase inhibitor and can cross the blood-brain barrier, a capability no prior approved Gaucher therapy had.
  3. In a 52-week clinical study of 43 patients, those who took Infilbray showed neurological improvement compared to those who continued on enzyme replacement therapy.
  4. The drug carries serious psychiatric warnings, including reported cases of suicidal thoughts and behavior, and was granted both Orphan Drug designation and Priority Review.

The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets. It is the first drug approved to treat the neurological symptoms of Type 3 Gaucher disease. The approval covers adults and children who weigh at least 15 kg, about 33 pounds. For patients with this rare inherited condition, it marks the first time an approved medication can reach the brain to target those symptoms.

Infilbray is made by Genzyme Corporation, a Sanofi Company. Patients take it as a tablet once a day. The FDA's approval announcement explains that the drug can cross the blood-brain barrier, a protective layer that controls what enters the brain. That ability sets it apart from all prior approved therapies for Gaucher disease.

What Type 3 Gaucher disease is

Gaucher disease is a rare, inherited condition. The body cannot produce a working enzyme needed to break down certain fatty substances known as glucosphingolipids. Without that enzyme, those compounds collect in organs, tissues, and throughout the brain. The buildup leads to a range of serious health problems that can worsen over time.

Type 3 Gaucher disease differs from type 1 in a key way. Type 1 mainly affects organs such as the liver and spleen. Type 3 also involves the brain and nervous system. That added dimension makes the condition significantly more complex to treat.

People with type 3 may struggle with balance and coordination. Speech can become difficult as well. Memory and clear thinking can also decline over time. These neurological symptoms tend to worsen gradually. That progression can seriously limit a person's ability to manage daily life. Unlike organ-related effects, neurological symptoms have been especially hard to address because existing therapies could not reach the brain.

Advertisement

Why an FDA-approved Gaucher disease drug targeting the brain matters

Enzyme replacement therapy has been the main approach to treating Gaucher disease for many years. These therapies go into a vein through an IV. They reduce harmful substance buildup in the body's organs and tissues. For many patients, they help control the non-neurological side of the disease effectively.

Advertisement

The limitation has always been the brain. Enzyme replacement therapies cannot cross the blood-brain barrier. That protective layer keeps many substances out of the brain, including these IV treatments. So the neurological symptoms of type 3 had no approved treatment aimed directly at them before this decision.

Infilbray takes a different approach. It is classified as a glucosylceramide synthase inhibitor, meaning it blocks a step in the body's production of these harmful substances. Because it can cross the blood-brain barrier, it reduces buildup inside the brain itself. That is a capability no prior approved Gaucher therapy had.

What the clinical trial showed

The FDA's decision rests on data from a 52-week clinical study. The study ran at multiple sites and used a randomized, double-blind design. That approach is the standard for high-quality medical research.

The study enrolled 43 patients aged 12 and older, all diagnosed with type 3 Gaucher disease. Each participant had been on enzyme replacement therapy before joining the study. Their non-neurological disease had been stabilized before they enrolled.

Advertisement

Participants were assigned to one of two groups. One group took Infilbray by mouth once a day. The other received IV enzyme replacement every two weeks. Both groups were followed for the full 52 weeks.

Two tests measured neurological change. One tracked ataxia, meaning impaired muscle control and coordination. The other measured cognitive function, covering areas such as memory and thinking. At week 52, the Infilbray group showed improvement on a combined score from both tests. The group that stayed on enzyme replacement alone did not show the same gains.

Side effects and safety warnings

Infilbray has known side effects. Stomach and digestive issues were the most commonly reported. Nausea and other gastrointestinal effects were noted during clinical use. Mood-related side effects have also been reported by some patients.

The drug carries a serious psychiatric warning. Cases of suicidal thoughts and behavior have been reported. Patients, their families, and medical teams should watch for any shifts in mood, thinking, or behavior during treatment. Regular check-ins with a doctor are important throughout therapy.

Advertisement

Animal studies identified two other risks. Younger patients may face a potential risk of vision clouding. The drug may also affect fetal development. Anyone who could become pregnant should discuss these risks with their doctor before starting the medication. Full safety information is in the drug's official labeling.

How the FDA classified Infilbray during review

The FDA gave Infilbray two special designations during the development process. The first was Orphan Drug designation. This status is reserved for drugs that treat rare conditions with small patient populations. It provides specific benefits designed to encourage companies to invest in treatments for diseases that might otherwise be overlooked.

Nonprofit spotlight

The second designation was Priority Review. This status allows the FDA to shorten its standard review timeline. It applies to drugs that may offer a meaningful advance for patients with serious conditions.

Genzyme Corporation, a Sanofi Company, holds the approval and will oversee the drug's availability to patients. The company submitted the application that led to the FDA's decision.

What this approval means for patients and families

Acting FDA Commissioner Kyle Diamantas noted that for type 3 patients, "harmful substances build up in the brain without a way to stop them," per the FDA press release. He added that the approval "reflects the FDA's commitment to advancing therapeutic options for patients with rare diseases."

For people living with type 3 Gaucher disease, this decision opens a treatment path that did not exist before for brain-related symptoms. Coordination problems, speech difficulties, declining memory, and other nervous system effects now have an approved drug aimed at their source.

The approval covers both adults and children. The minimum weight requirement of 15 kg, roughly 33 pounds, includes many younger patients. Because Gaucher disease can affect people at any age, extending an approved option to children is a meaningful part of this decision.

Patients currently on enzyme replacement therapy should speak with their doctors about whether Infilbray fits their treatment plan. The clinical trial enrolled people who had already been stabilized on that therapy. Any switch should be planned carefully with a physician who knows the patient's full history.

Advertisement

Sources